The invention provides an in-vitro or ex-vivo method for transiently modifying immune cells in a closed processing system comprising the steps: (i) providing immune cells from a biological liquid and/or from a resected tumor from a patient; (ii) purifying the immune cells; (iii) transfecting the purified immune cells with an inhibitory nucleic acid of a immunosuppressive regulator of the immune cells or with a nucleic acid of an immune enhancing factor; (iv) rebuffering the transfected immune cells into a physiological solution; (v) transferring the transfected immune cells into a container; wherein the transitions between steps (i) to (v) are in a closed container system; and a therapy using the transfected immune cells.
The present invention provides a method of a treatment or prophylaxis of a SARS-CoV-2 infection in a subject comprising administering an ACE2 polypeptide to the subject, wherein the SARS-CoV-2 infection is with a SARS-CoV-2 variant exhibiting an increase of ACE2 polypeptide binding affinity for SARS-CoV-2 spike protein mutants in comparison to wild type SARS-CoV-2 spike protein and a method of a treatment or prophylaxis of a coronavirus infection in a subject comprising administering an ACE2 polypeptide to the subject, wherein the ACE2 polypeptide is administered by inhalation, wherein a solution of ACE2 polypeptides is aerosolized into aerosol particles with an average particle size of 0.1 µm to 100 µm and at a dose of 100 µg to 600 mg daily.
The invention provides a combination of a SARS-CoV-2 cellular entry receptor and a viral proliferation inhibitor for the treatment of a SARS-CoV-2 infection and combined pharmaceutical preparations and kit-in-parts.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 31/245 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p. ex. procaïne, novocaïne
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (Autriche)
THE UNIVERSITY OF BRITISH COLUMBIA (Canada)
Inventeur(s)
Penninger, Josef
Wirnsberger, Gerald
Abrégé
Provided herein are methods for treating or preventing infection of a subject by a virus that infects the subject through angiotensin converting enzyme 2.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
5.
BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES
The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 281/10 - Cycles à sept chaînons comportant les hétéro-atomes en positions 1, 4 condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle à six chaînons
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
6.
PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER
The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with lnterleukin-2 (IL-2wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.
The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.
The present invention relates to a method for treating a GD2 positive cancer by administering preparation comprising an anti-GD2 antibody to a patient, wherein the preparation is administered in a dose sufficient to induce tumor cell lysis (cytolysis threshold dose), and wherein said cytolysis threshold dose is administered until the predetermined overall patient dose has been administered.
The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti- GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
The invention discloses a pharmaceutical composition comprising recombinant human superoxide dismutase (rhSOD) for preventing or treating one or more adverse reactions caused by treatment with an EGFR inhibitor in a subject.
ACE2 activating compounds for prevention and treatment of cardiovascular disease, kidney disease, lung disease and hypertension are disclosed. Also disclosed are methods of diagnosing cardiovascular disease, kidney disease, lung disease and hypertension by measuring ACE2 expression or nucleotide polymorphism analysis.
The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.
The present invention relates to methods for determining intracellular Cbl-b protein in cells of a sample, comprising introducing into a cell an antibody that binds Cbl-b intracellularly, allowing the antibody and potentially present Cbl-b proteins to contact in the cell, detecting binding events between the antibody and Cbl-b, quantifying the detected binding events, whereby the content of Cbl-b protein is determined.
The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen.
The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.
